Sabra Healthcare Reit Stock Z Score
| SBRA Stock | USD 16.76 0.18 1.09% |
Sabra | Z Score |
Sabra Healthcare REIT Company Z Score Analysis
Sabra Healthcare's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Sabra Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Sabra Healthcare is extremely important. It helps to project a fair market value of Sabra Stock properly, considering its historical fundamentals such as Z Score. Since Sabra Healthcare's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sabra Healthcare's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sabra Healthcare's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
Based on the company's disclosures, Sabra Healthcare REIT has a Z Score of 0.0. This is 100.0% lower than that of the Diversified REITs sector and about the same as Real Estate (which currently averages 0.0) industry. The z score for all United States stocks is 100.0% higher than that of the company.
Sabra Healthcare Current Valuation Drivers
We derive many important indicators used in calculating different scores of Sabra Healthcare from analyzing Sabra Healthcare's financial statements. These drivers represent accounts that assess Sabra Healthcare's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Sabra Healthcare's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 3.6B | 3.0B | 2.9B | 3.3B | 3.0B | 1.6B | |
| Enterprise Value | 5.9B | 5.2B | 5.5B | 5.7B | 5.1B | 3.2B |
Sabra Healthcare ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sabra Healthcare's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sabra Healthcare's managers, analysts, and investors.Environmental | Governance | Social |
Sabra Healthcare Institutional Holders
Institutional Holdings refers to the ownership stake in Sabra Healthcare that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Sabra Healthcare's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Sabra Healthcare's value.| Shares | Northern Trust Corp | 2024-09-30 | 3.3 M | Deutsche Bank Ag | 2024-09-30 | 3.1 M | Hhg Plc | 2024-09-30 | 2.8 M | Norges Bank | 2024-06-30 | 2.8 M | Nuveen Asset Management, Llc | 2024-09-30 | 2.6 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 2.4 M | Wellington Management Company Llp | 2024-09-30 | 2.4 M | Amvescap Plc. | 2024-09-30 | 2.3 M | Systematic Financial Management Lp | 2024-09-30 | 2.3 M | Blackrock Inc | 2024-09-30 | 35.6 M | Vanguard Group Inc | 2024-09-30 | 34.9 M |
Sabra Fundamentals
| Return On Equity | 0.0346 | ||||
| Return On Asset | 0.0283 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.36 % | ||||
| Current Valuation | 6.36 B | ||||
| Shares Outstanding | 236.59 M | ||||
| Shares Owned By Insiders | 1.29 % | ||||
| Shares Owned By Institutions | 99.60 % | ||||
| Number Of Shares Shorted | 17.89 M | ||||
| Price To Earning | 67.37 X | ||||
| Price To Book | 1.43 X | ||||
| Price To Sales | 5.80 X | ||||
| Revenue | 647.51 M | ||||
| Gross Profit | 466.9 M | ||||
| EBITDA | 311.81 M | ||||
| Net Income | 13.76 M | ||||
| Cash And Equivalents | 49.05 M | ||||
| Cash Per Share | 0.21 X | ||||
| Total Debt | 2.45 B | ||||
| Debt To Equity | 0.76 % | ||||
| Current Ratio | 0.78 X | ||||
| Book Value Per Share | 11.60 X | ||||
| Cash Flow From Operations | 300.57 M | ||||
| Short Ratio | 8.79 X | ||||
| Earnings Per Share | 0.41 X | ||||
| Price To Earnings To Growth | 3.15 X | ||||
| Target Price | 19.75 | ||||
| Number Of Employees | 48 | ||||
| Beta | 1.24 | ||||
| Market Capitalization | 3.97 B | ||||
| Total Asset | 5.39 B | ||||
| Retained Earnings | (1.72 B) | ||||
| Working Capital | 311.89 M | ||||
| Current Asset | 17.25 M | ||||
| Current Liabilities | 35.18 M | ||||
| Annual Yield | 0.07 % | ||||
| Five Year Return | 9.02 % | ||||
| Net Asset | 5.39 B | ||||
| Last Dividend Paid | 1.2 |
About Sabra Healthcare Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sabra Healthcare REIT's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sabra Healthcare using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sabra Healthcare REIT based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sabra Healthcare REIT offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sabra Healthcare's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sabra Healthcare Reit Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sabra Healthcare Reit Stock:Check out Sabra Healthcare Piotroski F Score and Sabra Healthcare Valuation analysis. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Diversified REITs space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sabra Healthcare. If investors know Sabra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sabra Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.111 | Dividend Share 1.2 | Earnings Share 0.41 | Revenue Per Share | Quarterly Revenue Growth 0.107 |
The market value of Sabra Healthcare REIT is measured differently than its book value, which is the value of Sabra that is recorded on the company's balance sheet. Investors also form their own opinion of Sabra Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Sabra Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sabra Healthcare's market value can be influenced by many factors that don't directly affect Sabra Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sabra Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sabra Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sabra Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.